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Summary.-Double stranded RNA (dsRNA) whether isolated from a fungal virus
or prepared synthetically (i.e., Poly I Poly C) and endotoxin were found to exert very
similar effects on syngeneic murine lymphomata and fibrosarcomata. They cause
complete regressions of some established subcutaneous (s.c.) or intradermal (i.d.)
tumours but not of intraperitoneal (i.p.) tumours when administered either systemi-
cally or directly into the tumour. To achieve this effect the tumours must be fully
established and the best results were obtained when treatment was started 7 days
after transplant. If treatment is started within the first 3 days following the trans-
plantation of the tumour then only a slight inhibition of growth rate was observed.
These agents can also act prophylactically and protect mice against a subsequent
challenge but only if this is given i.p. and not if given s.c. or i.d. The prophylactic
action is explained by the action of dsRNA and endotoxin on peritoneal macro-
phages which cause them to become cytotoxic to tumour cells (i.e., to become
activated).
The therapeutic effect of systemically administered endotoxin and dsRNA on
established tumours is not the result of a direct action on the tumour cells themselves
but is a complex process requiring the co-operation ofseveral hostfactors. Haemor-
rhagic necrosis involving coagulation is essential (i.e., heparinization reduces the
regression of tumours) but is not itself sufficient. Immunosuppression by whole
body irradiation or by antilymphocyte serum also interferes with the antitumour
action of dsRNA and endotoxin in spite of the fact that haemorrhagic necrosis still
occurs. Also, the magnitude of the antitumour action correlated in a series of
different tumours with their antigenicity. The observed tumour regressions are
probably brought about by (1) vascular damage in the tumour which permits
immune defence mechanisms of the host to gain access to the tumour and (2) acti-
vation of macrophages present within the tumour. The relative contribution of
these two mechanisms may depend on the nature of the tumour and the route of
administration of the active agents.
Dibenyline, which protects against the lethal action of endotoxin by preventing
the action of the catecholamines on the a-adrenergic receptors, makes it possible to
increase the effectiveness of endotoxin in tumours by allowing a large dose to be
given. Lipid A, a derivative of endotoxin which does not contain polysaccharide,
has similar antitumour action to dsRNA and endotoxin. Some common features
of the chemical structure of lipid A and dsRNA are discussed.
Over a hundred years ago (Busch (Coley'stoxin),whichcontainedendotoxins
1866), a Viennese physician noted that amongst many other components, and
regressions of some malignant tumours achieved some very striking results (cf.
appeared to coincide with the occurrence review by Nauts, Fowler and Bogatko,
of erysipelas. Coley, having made a 1953). The subject of the antitumour
similar observation, deliberately treated action of endotoxins has attracted much
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but from aii experimental standpoint, the
key publication is that of Andervont
(1936), in which he showed that large
pritnary chemically-induced epitheliomata
of mice regressed completely following
systemnic treatment with endotoxin and
that these striking effects were associated
with a haemG-irrhagic reaction and resul-
tant damage of the tumour vasculature.
Using primary as well as transplanted
tumours in syngeneic systems, Andervont
found that endotoxin was effective only
after tumours had become fully established
and was inactive when given immediately
after a transplant. Double-stranded
RNA (dsRNA) both of natural origin
(e.g., when isolated from fungal viruses)
and when prepared synthetically (i.e.,
Poly I Poly C) mimics many of the
biological actions of endotoxin, such as
toxicity and interferon induction. Both
types of dsRNA have also been. found to
slowthe growth ofavariety oftransplanted
mrouse tumours and leukaemias (Levy,
Law anid Rabson, 1969; Pilch anid Plan-
terose, 1971). Typical endotoxin-type
i,ntitumour action (i.e., an effect which
predominantly affected established
tumour) had been recognized for dsRNA
by Pilch and Plaiterose (1971) but in
most ofthe other studies this was not noted
because in general the dsRNA was
administered soon after transplantation
of the tumours.
Our interest in the antitumour activi-
ties of endotoxin and of dsRNA derived
from the observation that after exposure
to either of these substances int vivo or
in vitro, peritoneal macrophages acquired
the capacity to inhibit the growth of
lymphoma and sarcoma cells (Alexander
and Evans, 1971). Neither endotoxin
nor dsRNA, at the concentrations used
to treat macrophages, have a direct effect
on the growth oftumour cells in vitro. The
term " activated " has beenused to describe
inacrophages that have acquired the
capacity to inhibit in vitro the growth of
tumour cells that are in direct contact with
them and they need to be distinguished
froml .armed" macrophages which kill
tumour cells in an immunologically specific
way. Since the growth inhibitory effect of
activated macrophages is confined to
tumour cells (Hibbs, Lambert and Rem-
m.ington, 1972), it seemed possible that
such macrophages might be concerned
with the in vivo antitumour activitv of
dsRNA and endotoxin.
The aim of the present study was to
determine the conditions under which
dsRNA of fungal origin and endotoxin
inhibit the growth of established tumours.
The induction of interferon by (IsRNA
may account for its inhibition of viral
careinogenesis (cf. review by Hilleman,
1 970), but cannot explain its action on
gro;ving t-amours iU vhvo. Both dsRNA
and endotoxin have been shown under
sotne conditions to act as immune adju-
vants and to cause a nonspecific stimula-
tion of the immune systems, and Levy
(1970) has attributed the effect of dsRNA
as an antitumour agent to this property.
While it has been clearly shown that much
more potent stimulants of the immune
system than dsRNA, s-uch as mycobac-
teria (e.g., BCG) and (1orynebacteriunm
parvum, render rodents more resistant to a
subsequent challenge with tumour cells
(Halpern etal., 1959, 1966; Old etal., 1961),
such agents have only a minor therapeutic
effect when given after the tumour has
been injected (Mathe, Pouillant and
Rapeyraque, 1969; Parr, 1972). They
are without effect on established tumours,
and are active only in an animal with
pre-existing tumour when the number
of such tumnour cells is very small. On
the other hand, endotoxin, as first shown
by Andervont (1936), and dsRNA, as
shown in this paper, are most effective
against established tumours an(d almost
ineffective when there are only a few
tumour cells present in the animal.
It would seem that mechanisms othei
than induction of interferon or non-
specific stimulation of the immune system
must come into play in the pronounced
antituinour action shown by dsRNA and
endotoxin against solid tumours.
Structurally, these two classes of
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macromolecules are very different. How-
ever, Luderitz and colleagues (cf. review
1970) have shown convincingly that a
polysaccharide-free derivativeofendotoxin
referred to as lipid A will, if suitably
solubilized, mimic many of the biological
actions of endotoxin. This applies also
to the activation of macrophages (Alex-
ander and Evans, 1971) and, as shown in
the present investigation, to the anti-
tumour action in vivo. Possible structural
similarities of dsRNA and Lipid A are
referred to in the Discussion.
MATERIALS AND METHODS
Mice.-Ten-week old mice, CBA, C57B1
and DBA/2, were supplied from breeding
colonies maintained in the Institute under
specific pathogen-free conditions.
Tumours.-Two tumours, a lymphoma
L5178Y and a fibrosarcoma FS6, were used
for the majority of the experiments. Brief
details of these and the other tumour lines
used are given in Table I. The lymphomata
were maintained in the ascitic form by serial
weekly passage of washed, counted tumour
cells into the strain of origin. Transplant of
the fibrosarcomata was fortnightly by means
of trocar fragments. At 4-5 monthly inter-
vals the tumours were re-established from
stock tumour cell lines maintained in liquid
nitrogen. Single cell suspensions were pre-
pared from the fibrosarcomata by enzymic
digestion of minced tissues with TC.199
medium containing 0.13% trypsin, 0.13%
collagenase and 0 002% DNAase for 15
min at room temperature.
Subcutaneous or intradermal challenges
were made into the right flank ofthe animal.
Growth of tumour was followed by bi-weekly
measurement of two diameters by means of
calipers.
dsRNA, which was kindly supplied by
Beecham's Research Laboratories, was from a
fungal virus obtained from a penicillin
mould (Planterose et al., 1970). Poly I Poly C
was obtained from Mlles Laboratories Inc.
(Enhard, Indiana). Endotoxin was a highly
purified water-soluble preparation of lipo-
polysaccharide from Shigella which was
kindly donated to us by Dr D. A. L. Davies.
'All the above 3 substances were injected
in saline or TC.199 in volumes of 0-1 ml and,
except where stated, were given i.p.
The following endotoxin derivatives were
kindly donated by Professor 0. Westphal
(of the Max Planck Institute for Immuno-
biology, Freiburg, Germany) and are des-
cribed by Galanos et al. (1971): A glycolipid
from Salmonella minnesota (R595) which
was dissolved in water by heating in a water
bath for 2 minutes. Lipid A from S. minne-
sota (R345) which had been rendered soluble
in water by 3 methods: with the aid of
pyridine, by treatment with NaOH (1 hour at
56TC) and by complexing with bovine serum
albumin (BSA) in a 12 : 1 BSA/Lipid A ratio.
Isotonic solutions for injection (i.p.) were
prepared by addition of concentrated saline
to solutions ofLipid A in water. Dibenyline
was obtained from Smith, Kline and French
laboratories. Mice received 100 jug/animal
in volumes of 1 ml injected i.p. 2 hours before
administration of endotoxin. Mice received
3 injections (s.c.) each of 100 iu heparin per
24 hours. Fine needles (gauge 30) were used
to minimize the numbers of deaths from
bleeding.
Antilymphocyte serum was prepared by
sensitizing rabbits with mouse thymocytes
according to the method described by Sutthi-
wan et al. (1969). Eight injections of 0-1 ml
of ALS were given i.p. on alternate days,
beginning 2 days after tumour transplant.
TABLE I.-Summary ofDetails of Origin of Tumours Described in Text
Method of induction
Methylcholanthrene
Arose from L5178Y
Spontaneous
Methyleholanthrene
Whole body
x-irradiation
Benzpyrene pellet
Benzpyrene pellet
Benzpyrene pellet
Benzpyrene pellet
Tumour
L5178Y
L5178Y-M
SL2
TCL5
TLX9
FSI
FS6
FS9
FSII
Type
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Lymphoma
Fibrosarcoma
Fibrosarcoma
Fibrosarcoma
Fibrosarcoma
Mouse of
origin
DBA/2
DBA/2
DBA/2
CBA
C57B1/6
C57B1/6
C57B1/6
CBA
CBA
Date
1961
1968
1968
1968
1967
1969
1970
1970
1970
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Whole body x-irradiation of400 rad at the
rate of 83 rad/min was delivered from a 220
kVp Marconi unit without filtration.
Prednisolone acetate was obtained from
Roussel Laboratories, England. Mice were
injected s.c. with 1-2 mg of prednisolone
acetate 24 hours before receiving endotoxin.
RESULTS
In the first series of experiments
tumour cells were injected under the skin
ofthe mouseandtumourgrowth waspartly
i.d. and partly s.c. In later experiments
(see page 376) care was taken to inject
the cells either wholly below (i.e., s.c.) or
wholly above (i.e., i.d.) the muscle layer-
panniculus carnosus-present in the skin
of all rodents.
A. Effect of dsRNA and endotoxin on
established s.c.-i.d. lymphomata and
sarcomata
1. Timing of dsRNA and endotoxin
Lymphoma.-Neither dsRNA norendo-
toxin (injected i.p. or i.v.) given before
inoculation of tumour cells s.c. (in the
flank) had any effect on the growth of the
L5178Y lymphoma in syngeneic mice
(Table II). A significant effect on the
growth of a s.c. tumour was observed only
when the treatment with dsRNA or
endotoxin was delayed until a palpable
tumour mass was present. This is illus-
trated in Fig. 1 in which one group of
mice were injected i.p. with 100 jag of
dsRNA twice weekly beginning 24 hours
after transplant of 106 L5178Y cells s.c.,
while in another group of animals treat-
ment wasdelayed until 7 daysafter tumour
transplant, by which time the tumours
were 8 mm average diameter. In the first
group there was little inhibition oftumour
growth, whereas in the second, tumour
necrosis occurred within 24 hours of treat-
ment followed by tumour regression. In
Fig. 1 the use of " average diameters "
to record the response ofthe group treated
on Day 7 became meaningless after 25
days because mice divided into two
distinct categories-animals in which
tumours had completely regressed and
mice with re-growing tumours. No
tumour necrosis or regression was noted
in the group of mice treated from Day 1
onwards in spite of the dsRNA injections
being carried on over the same period as
the group started Day 7. Endotoxin
caused tumour regression ofa solid tumour
only if administered after the tumour had
become established and presumably vascu-
larized. Fig. 2 illustrates an experiment
in which a single dose of endotoxin was
given either one or 7 days after the
inoculation of tumour cells.
The dose response curve forthe activity
of dsRNA against an i.d. L5178Y lym-
phoma plateaus between doses of 50 ,tg
and 100 1ag given twice weekly (Table
III). Five doses of 100 jug of dsRNA
given twice weekly were close to the
maximum tolerated dose and 150 ,ug
caused some deaths. While a single
injection of 100 jug of dsRNA had no
detectable effect on tumour growth, one
of 300 ,ug caused tumour regression (Table
III). This dose, however, could not be
toleratedunderallconditions sinceenviron-
mental factors affect toxicity. Both the
toxicity and antitumour activity of endo-
toxin are very dependent on the tempera-
ture at which the animals are maintained
and no attempt was made to establish a
dose-response curve. Under normal con-
ditions in the animal house (i.e., 25°c)
10 jug of endotoxin regularly caused
tumour regression. Increasing the dose
to 15, 20 and 25 ,ug did not improve the
antitumoir effect and the latter made the
mice obviously sick. Consequently a
dose of 10 jag/mouse was used throughout.
However, under conditions of above
average environmental temperature (i.e.,
in the range 26-29°C) 1 jag endotoxin per
mouse was sufficient to induce permanent
tumour regression in 4/5 animals.
Attempts to give repeated doses of 10 jag
of endotoxin resulted in the death of
50% of the animals.
Fibrosarcomata.-The initial experi-
ments were made on mice carrying trocar
fragments of tumour placed in the flank.
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FIG. 1.-Effect of dsRNA on L5178Y growing in skin as solid lymphoma. 106 L5178Y cells injected
s.c.-i.d. dsRNA 100 ,ug 2 x weekly injected i.p. beginning (A) 24 hours after tumour transplant
and (B) 7 days after transplant.
Controls and Group A: All tumours grew progressively into large masses. Group B: 3/5 of the
tumours recurred and grew into large masses while 2/5 were in total regression on Day 40 when
the experiment was terminated.
TABLE II.-Effect of dsRNA and Endotoxin Given at Various Times Before and
After Implant ofL5178Y s.c.-i.d. in Skin ofSyngeneic (DBA/2) Mice
Effect on tumour growth
A
Time of
administration
7 days before
implant
3 days before
implant
-1 day before
implant
1 day after
implant
7 days after
implant
Treatment
Endotoxin
dsRNA
Endotoxin
dsRNA
Endotoxin
dsRNA
Endotoxin
dsRNA
Endotoxin
dsRNA
None
None
5/5
5/5
5/5
5/5
5/5
5/5
5/5
5/5
0/5
0/5
5/5
Slowing*
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
Temporary
regressiont
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
1/5
3/5
Permanent
regression§
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
4/5
2/5
106 L5178Y were injected s.c.-i.d. in the flank.
10 jig endotoxin given i.p.
100 sg dsRNA given i.p. bi-weekly for 21 weeks.
Figures denote No. of mice showing effect Total number in experiment
* Slowing of growth was defined as tumour size not increasing for at least 5 days after treatment or
decreases in average diameter < 2 mm.
t Temporary regression was defined as decrease in average diameter of tumour > 2 mm. § Permanent regression, survivors remained fit for 3 months after treatment.
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FIG. 2.-Effect of endotoxin on L5178Y lymphoma growing i.d.
Controls 3 x 106 cells i.d. Group A: 3 x 106 cells i.d.-endotoxin 10 JAg i,p. injected Day 1 after
tumour transplant. All tumours grew progressively. Group B: 3 x 106 cells i.d.-endotoxin
10 Mg i.p. injected Day 7 after tumour transplant. 1/5 tumours recurred while 4/5 regressed
permanently.
TABLE IlI.-Do8e-response Chart of Antitumour Effect8 of dsRNA on L5178Y
Lymphoma Growing i.d.
Total of
5 doses/
mouse given
twice weekly
starting 7
days after
i.d. transplant
Substance 106 cells
dsRNA 1 ug
12 Mzg
25 ug
50 pg
100 Mg
300 Mgt
1 dose only
Degree of
haemorrhagic
necrosis
++
+ ++
Average
diameter
of tumours
(mm) on
day of
treatment
7 0
7.5
7.5
8-5
7 0
5 0
Effect on tumour growth*
K~~~~~
None
4/5
5/5
0/5
1/5
0/5
0/5
Slowing
1/5
0/5
3/5
1/5
0/5
2/5
Temporary
regression
0/5
0/5
0/5
2/5
3/5
1/5
Permanent
regression
0/5
0/5
2/5
1/5
2/5
2/5
* Defined in Table I.
t Different sample of dsRNA.
In an experiment similar to the one
described for the lymphoma, dsRNA
treatment (100 ,ug twice weekly) was
started in different groups of mice 1, 10,
16 and 20 days after transplant of FSI
fibrosarcoma (Fig. 3). The most notice-
25
able tumour regression occurred when
treatment was delayed until a palpable
tumour mass was present. With con-
tinued serial transplant this tumour
became less responsive to dsRNA treat-
ment and in subsequent experiments the
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activity of endotoxin against fibro-
sarcomata was studied using the FS6
fibrosarcoma which was stored at 1700C
and transplanted throughout from a
given passage (see Experimental section).
Endotoxin (10 ,ug/mouse) was given to
various groups of mice on Days 1, 7, 9 and
15 after implant of 5 x 10 FS6 cells i.d.
The experimental results are presented in
the form of a graph of average tumour
diameters plotted against time in Fig. 4
and in terms ofthe final effect ofthe treat-
ment on tumour growth in Table IV. The
fibrosarcoma, like the lymphoma, res-
ponds to dsRNA and endotoxin only if
the tumour is established when treatment
is begun.
2. Site of tumour transplant
Peritoneal. Intraperitoneal (ascitic)
tumours of L5178Y do not respond to
dsRNA and endotoxin treatment in the
same way as s.c. or i.d. lymphomata. No
inhibitory effect on tumour growth was
observed when dsRNA or endotoxin was
given to mice 1, 3 or 7 days after i.p.
inoculation of lymphoma cells. On the
other hand, some protection was afforded
when dsRNA or endotoxin was injected
3 or 7 days before the tumour cells were
injected i.p. (Table V).
Subcutaneous versus Intradermal In
the initial experiments it was noted that
the most marked tumour regressions
occurred in those animals in which some
tumour cells had been accidentally injected
into the dermis. When the tumour cells
were injected with more care, either all
i.d. or all s.c. (106 L5178Y cells/mouse)
then both dsRNA and endotoxin had a
more pronounced antitumour action on
tumours growing i.d. (Table VI). In the
case of fibrosarcomata FSI and FS6 this
difference in the reaction of i.d. and s.c.
tumours was not observed but the situa-
tion was complicated since s.c. injected
fibrosarcoma cells grew more slowly than
those injected i.d.
3. Intralesional route of administration-
dsRNA
Injection of dsRNA directly into the
tumour mass was more effective than
intraperitoneal inoculation. Table VII
shows that 100 ,ug of dsRNA injected into
L5178Y lymphoma induced greater inhibi-
tion oftumour growth than 5 similar doses
given i.p. This response was not increased
by repeated intralesional inoculation. On
the other hand, for the fibrosarcomata
repeated injections of dsRNA into the
tumour were necessary to achieve perm-
anent regression. The toxicity of dsRNA
given intralesionally was less than when
given by the intraperitoneal route.
TABLE IV. Effect of Endotoxin on Murine Fibrosarcoma FS6*
Average diameter
tumour on day of
treatment
Not palpable
4-5
5 0
8-0
Effect on tumour growtht
Temporary Permanent
None Slowing regression regression
5/5 0/5 0/5 0/5
5/5
0/5
1/5
0/5
0/5
3/5
0/5
1/5
0/5
1/5
2/5
3/5
Time of
endotoxin
injection
(10 ,ug/mouse
i.p.)
No
endotoxin
Day ] after
tumour
Day 7 after
tumour
Day 9 after
tumour
Day 15 after
tumour
* 5 x 105 FS6 cells were injected i.d.
t Defined in Table II.
0/5
1/5
2/5
1/5
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FIG. 3.-Effect of dsRNA treatment (100 ,ug 2 x weekly) begun at various times-24 hours (Group A), 10 (Group B), 16 (Group C) and 20 (Group D) days after transplant of FSI fibrosarcoma by means of trocar piece.
Controls and Group A: Alltumours grewprogressively. Group B: 5/5 tumours were " slowed "but soon resumed original rate of growth. Group C: 3/5 tumours regressed temporarily but recurred later. Group D: 1/5 tumours regressed permanently. 1/5 mice died after first dsRNA injection. 3/5 tumours exhibited slowed growth rate.
TABLE V.-Effect of dsRNA and Endotoxin on Growth ofIntraperitoneal
L5178Y Lymphoma
No. of animals alive
Total in experimental group
Type of treatment
7 days before transplant of tumour*
3 days before transplant of tumour
1 day before transplant of tumour
1 day after tumour transplant
7 days after tumour transplant
7 days before transplant of tumour
3 days before transplant of tumour
1 day before transplant of tumour
1 day after tumour transplant
1 day after tumour transplant
7 days after tumour transplant
Days after tumour transplant: 30 40 50
0/20
12/20
10/10
0/5
0/5
0/5
7/10
2/5
0/5
0/5
0/5
0/10
8/20 4/20
5/10 3/10
3/10 3/10
1/5 0/5
* 104 L5178Y lymphoma cells given i.p.
t 10 ,ug endotoxin was injected i.p. § 100 ,ug dsRNA was injected i.p.
11 100 ,ug dsRNA 2 x weekly.
None
Endotoxint
dsRNA§
dsRNA
repeated
startingfl
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Control
B ,
I I I
5 10 15
Time in days
20 25 30
Fic. 4.-Effect of endotoxin given at various times after tumour transplant on growth of FS6 fibrosarcoma.
Controls: 5 x 105 FS6 cells i.d. Group A: 5 x 105 FS6 cells i.d.-IO jg endotoxin i.p. Day 7 after transplant of tumour. Group B: 5 x 105 FS6 cells i.d.-1O rg endotoxin i.p. Day 9. Group C: 5 x 105 FS6 cells i.d.-1O ,ug endotoxin i.p. Day 15.
See Table IV for final result of treatment.
4. Appearance of treated skin tumours
(a) Macroscopic.-Treatment with
either dsRNA or endotoxin gave rise to
very similar macroscopic changes in the
treated intradermal tumours although
dsRNA was rather slower in producing the
characteristic tumour necrosis. Within
6-8 hours of administration of 10,ug of
endotoxin i.p. a reddening of the tumour
surface was apparent. This discolour-
ation gradually became darker, until at
24 hours most of the tumour surface
(most easily seen in the case of L5178Y
growing in the light-coloured skin of
DBA/2 mice) was covered by a dark
haemorrhagic-looking area. The under-
lying tumour tissue was generally softer
than that of the controls. During the
next 2 days a dark crusty scab developed
at the tumour site. Complete cure or
failure became obvious during the second
week, when in some animals the dried
black crust continued to contract and
finally fell off, leaving a dermal scar,
whereas in others viable tumour had
re-grown around the area of tumour
necrosis. Macroscopic changes after
treatment were not particularly obvious
in tumours that were growing subcu-
taneously. Occasionally there was slight
reddening ofthe skin surface in some ofthe
tumours.
(b) Histology.-Within 30 minutes of
endoxin administration bloodvessels with-
in all of the tumours examined (i.e., s.c.
and i.d.) and surrounding dermal tissue
becamecopgested. By 24 hours extensive
extravasation of blood had occurred
within the i.d. tumours and to a much
lesser extent in the s.c. tumours. No
10
CZ
S- S
tumour
transplant
A .
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intrinsic vascular lesions were noted but
these could have been obscured by the
large degree of haemorrhage present. In
both i.d. and s.c. tumours local necrosis
was observed one hour after giving endo-
toxin and at 24 hours the histological
picture of the i.d. tumour was one of
extensive haemorrhage and necrosis
throughout the tumour, with little or no
viable tumour tissue. On the other hand,
in the s.c. tumour some necrotic foci were
scattered throughout with a certain small
degree ofhaemorrhage occurring but there
were still some viable tumour cells present.
TABLE VI.-Influence ofSite ofTumour Challenge (L5178Y Lymphoma) onAntitumour
Effects ofdsRNA and Endotoxin
Dose/mouse
injected
i.p. on
Day 7
after
tumour
Substance transplant
dsRNA 100 ,g
2 x week
5 doses
Endotoxin 10,g
dsRNA 100 mg
2 x week
5 doses
Endotoxin loTeg
Site of
challenge
with
106
L5178Y
cells
s.c.
Average
diameter
of tumour
at beginning
of treatment
(mm)
8-0
Effect on tumour growth*
Temporary Permanent
None Slowing regression regression
1/5 3/5 0/5 1/5
s.c. 8.0 0/5 1/5 3/5
i.d. 9 0 0/5 2/5 0/5
i.d. 8 5 0/5 0/5 1/5
Treatments were given i.p.
* Defined in Table II.
TABLE VII.-Effect of Direct Injection ofdsRNA into Tumour
1/5
3/5
4/5
Day of
Dose administration
Effect on fibrosarcoma (FS6)
25,ug 10
50,ug 10
100,ug 10
250 ,ug 10
500,ug 10
Saline 10
25,g 10, 13, 16, 20
50 jMg 10, 13, 16, 20
100 Mg 10, 13, 16, 20
250 /ug 10, 13, 16, 20
500,4g 10, 13, 16, 20
Saline 10, 13, 16, 20
Effect on lymphoma (L5178Y)
25,ug 7
50,ug 7
lOO,ug 7
250,ug 7
500,ug 7
Saline 7
3 ,ug 7, 10. 13, 17
6 Mg 7, 10, 13, 17
12 Mug 7, 10, 13, 17
25 MAg 7, 10, 13, 17
50 Mg 7, 10, 13, 17
Saline 7, 10, 13, 17
* Defined in Table II.
Effect on tumour growth*
Temporary Permanent
None Slowing regression regression
4/5
4/5
3/5
0/5
0/5
5/5
2/5
1/5
1/5
0/5
0/5
5/5
2/5
0/5
1/5
0/5
0/4
5/5
0/5
1/5
0/5
0/5
1/5
4/5
1/5
1/5
2/5
5/5
4/5
3/5
4/5
1/5
0/5
0/5
0/5
0/5
0/5
0/5
0/4
3/5
1/5
0/5
1/5
0/5
0/5
0/5
0/5
0/5
1/5
0/5
0/5
3/5
1/5
2/5
1/5
0/5
0/5
1/5
0/4
0/5
0/5
1/5
1/5
2/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
0/5
4/5
3/5
2/5
5/5
4/5
4/5
4/4
2/5
3/5
4/5
3/5
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The histology of turmours treated with
(IsRNA was examined only at 4 and 24
hours after administration ofthe drug and
the general appearance was indistinguish-
able from that of tumours treated with
en(lotoxin.
5. Relationship between antitumour
activity and antigenicity of tumour
The extent of tumour necrosis and the
incidence of tumour regression following
end(lotoxin treatment were greatest in the
more antigenic tumours, i.e., L5178Y and
FS6, and much less marked in those
lymphomata and fibrosarcomata which by
standard transplantation tests would be
considered less antigenic (see Table VIII).
On the other hand, there were occasionally
well defined areas of superficial necrosis
in those tumours, e.g., TLX9, FS9 which
failed to respond. In these latter tumours
there was no accompanying softening of
the surrounding tumour tissue which
continued to grow at the original rate.
B. Activity of structurally related
macromolecules
The marked similarities of the anti-
ttumour activities ofendotoxin and dsRNA
(e.g., the importance of timing, the failure
of established i.p. tumours to respond and
the appearance of the tumour after treat-
ment) raise the possibility that the activity
of dsRNA may be due to contamination
with endotoxin. However, this was
excluded when it was found that samples
of dsRNA which had previously been
treated with RNAase lost their antitumour
activity against i.d. L5178Y lymphoma
(see Table IX).
In the tumrour systems studied by us
the synthetically prepared Poly I Poly C
showed the same type of activity as the
(IsRNA from the fungal virus. The data
(see Table IX) are not sufficient to allow a
quantitative comparison ofthe one sample
of Poly I Poly C used and of the viral
dsRNA.
Ofparticular interest is that derivatives
of endotoxin kindly given to us by Dr 0.
Luderitz and Professor 0. AW'estphal
showed very similar antitumouir activity
to the Shigella endotoxin used in these
studies. A mutant strain of Salmonella
minnesota (Re) unable to synthesize poly-
saccharides produces a glycolipid with
endotoxin-like activity, in which lipid A
is linked through a ketone group to a
trisaccharide of 2-keto-3-deoxyoctonate
(KDO) (Droge et al., 1970). This sub-
stance is water soluble and is active
against established tumour. Lipid A,
obtained by Westphal and Liideritz (1954)
fromthisglycolipidbyacidhydrolysis, con-
tains no saccharides and is a sugar
phosphate polymer containing a lipid
side chain. Lipid A is completely insol-
uble in water but can be solubilized by
disaggregating agents such as pyridine or
by forming water-soluble complexes with
carriers such as bovine serum albumin
(BSA) (Galanos et al., 1971). Both lipid
A solubilized by pyridine and the lipidA-
BSA complex exhibited powerftil anti-
tumour action against L5178Y lymphoma
qualitatively indistinguishable from that
of endotoxin and dsRNA. Lipid A solubi-
lized by treatment with alkali was not
quite as active. For both lipid A and
the glycolipid the effective antitumour
dose was approximately 10 times higher
than that of endotoxin and little or no
tumour inhibition was noted with either
lipid A or glycolipid used in the dose
range 10-50 jig ;(Table IX). However,
the toxicity of the lipid A preparation is
very much lower than that of endotoxin
aind it is our impression unfortunately
we did not have sufficient material for
detailed toxicological studies that 250
lig of the lipid A-BSA complex produces
less toxicity in terms of disturbed gut
function and general appearance than
does 10 lig of endotoxin. G'alanos et al.
(1971) report that the LD50 of lipid A-
BSA for mice is in excess of 1000 lig and
in terms of " therapeutic index " it seems
possible that the lipid A-BSA is superior
to both endotoxin and dsRNA. However,
further experiments with a large batch of
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TABLE VIII.-Effect of Endotoxin on Various Syngeneic Tumours Transplanted i.d.
Lymphoma
L5178Y (DBA/2)
L5178Y-M (DBA/2)
TLX9 (C57B1)
TLC5 (CBA)
SL2 (DBA/2)
Fibrosarcoma
FSI (C57B1)
FS6 (C57BI)
FS9 (CBA)
FSll (CBA)
Antitumour effectt
+±+
+±+
Immunogenicity of
tumour*
+-
++
+
* Immunogenicity of the above lymphomata has been defined in terms of the number of cells rejected
after immunization with irradiated cells (the details are given by Parr, 1972). In the case of the sarcomata
the gradation is based on experiments in which immunization was by means of excision of the tumour.
These animals then resisted 5 x 106 FS6 or FSI sarcoma cells but with the CBA fibrosarcomata FS9,
FSI1, 5 x 106 cells grew into tumour in 7/10 such animals.
t -No effect.
+-A slowing of growth rate in some of the tumours.
+ + Some temporary regressions-no complete cures.
+ + + Complete cures in > 50 % of animals.
TABLE IX.-Effect of Different Macromolecules on the
Dose/mouse
injected
i.p. day 7
Substance after transplant
dsRNA 100 jMg
(5 times)
twice
weekly
dsRNA treated 100 Mg
with RNAase (5 times)
twice
weekly
Poly I Poly C 100 Mug
(5 times)
twice
weekly
Endotoxin
Glycolipid
Lipid A
solubilized
with BSA
Lipid A
solubilized
with pyridine
Lipid A
solubilized
with alkali
10Mig
50mg
100 Mig
50Mg
250 ,ug
250 Mug
L5178Y Lymphoma Growing i.d.
Effect on tumour growth*
Temporary
Necrosis None Slowing regression
+ + 4/15 5/15 1/15
5/5 0/5
2/6 2/6
+ +
0/15
5/5
1/9
4/5
0/11
0/15
0/5
4/9
1/5
1/11
+ + + 0/9 4/9
250 Mg 3/9 3/9
0/5
0/6
2/15
0/5
1/9
0/5
0/11
0/9
0/9
Permanent
regression
5/15
0/5
-1/6
13/15
0/5
3/9
0/51
10/11
5/9
3/9
* Defined in Table II.
lipid A are needed to establish these
quantitative aspects. From the point
ofview ofmechanisms it is clear, however,
that the polysaccharide components of
endotoxin are not required for the anti-
tumour action of endotoxin. Westphal
and his colleagues (1954) had previously
shown that several other biological activi-
tiesofendotoxinwerealso closelymimicked
by lipid A when suitably solubilized.
A
t
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C. Mechanism ofaction
1. Failure to detect a direct cytotoxic action
Alexander andEvans (1970) hadshown
that both lymphoma and sarcoma cells
grow normally tn vitro in the presence of
50 ,tg ofdsRNA or endotoxin. However,
at very much lower concentrations these
macromolecules " activate " macrophages
and render them cytotoxic to lymphoma
andsarcoma cells. Anapparent cytotoxic
action of these agents can be sometimes
observed in cultures of sarcoma cells
established from cells obtained directly
from a sarcoma. This effect, however, is
mediated by macrophages. Sarcomata in
mice and rats contain macrophages and
sometimes up to 40% of the cells derived
by enzyme digestion of a sarcoma are
macrophages (Evans, 1972). Conse-
quently, primary cultures established from
the cells of a sarcoma can constitute a
mixture of macrophages and sarcoma
cells; dsRNA and endotoxin act on the
macrophage component which then
inhibits the growth of sarcoma cells. If
the macrophages are removed from a
culture of sarcoma cells then dsRNA and
endotoxin at doses of 50,g/ml fail to
effectthegrowthofthesarcomacellsinvitro.
We decided to test whether endotoxin-
treated tumour cells grew normally in
vivo and accordingly 106 L5178Y lym-
phoma or 106 FS6 sarcoma cells prepared
by trypsin treatment of the respective
tumours were injected i.d. in 0*1 ml of
tissue culture fluid together with 5 ,ug of
endotoxin. Therateoftumourgrowth was
quite normal and the endotoxin was with-
outeffect(seeTableX). Cellsteasedmech-
anically from a sarcoma and injected
immediately i.d. into mice were occas-
ionally prevented from growing if 5#tg
of endotoxin were added to the cells
before injection. It was thought that
this occasional inhibition might be due
to an increase in the numbers of macro-
phages present in the cell suspensions
prepared from the tumours. To test this,
4 x 106 macrophages from the peritoneal
cavity ofnormal C57B1 mice were added
to a cell suspension of FS6 prepared
enzymically and the mixture injected i.d.
into mice. This mixture of cells gave rise
to normal tumours; however, if 5,ug of
endotoxin was added to the mixtures of
macrophages and sarcoma cells then there
was marked interference with tumour
growth (see Table X).
2. Vascular effects of endotoxin
Shwartzman (1937) and Andervont
(1936) attributed the effect of endotoxin
on established tumours to a haemorrhagic
reaction. The changes produced by endo-
toxin in tumours are in many respects
similar to a local Shwartzman reaction.
In the latter, necrosis is produced by
systemic administration of endotoxin fol-
TABLE X.-Effect ofin vitro Addition ofEndotoxin-in vivo Growth Assay
Effect on tumour growth*
,~~~~~~~ I
Cell mixture injected i.d.
Lymphoma 2 x 106 cells
+ 5 ,ug endotoxin
Trypsinized suspension of
FS6 105 cells + 5 pg endotoxin
Mechanical suspension of
FS6 10r cells + 5,ug endotoxin
Trypsinized suspension of
FS6 10' cells + 4 x 106
peritoneal macrophages
Trypsinized suspension of
FS6 105 cells + 5 pg endotoxin
+ 4 x 106 peritoneal
macrophages
* Defined in Table II.
tNo growth of tumour.
None
5/5
5/5
10/15
5/5
0/10
Slowing
0/5
0/5
0/15
0/5
0110
Temporary
regression
0/5
0/5
2/15
0/5
4/10
Permanent
regression
0/5
0/5
3/15
0/5
2/10 4/10t
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lowing an initial primary dose given
locally. The tumour vasculature without
prior exposure to endotoxin seems to
respond to endotoxin like the blood
vessels in skin after initial sensitization.
Since the local Shwartzman reaction can
be inhibited by administration of heparin
(Good and Thomas, 1953), the effect of
full heparinization on the antitumour
action of endotoxin was studied with both
L5178Y lymphoma and the FS6 sarcoma.
Twenty mice were heparinized on Day
7 after inoculation i.d. of 106 L5178Y cells.
Endotoxin (10 ,tg per mouse) was injected
into 10 of these animals 4 hours after the
first dose ofheparin. Injections ofheparin
(3 per 24 hours) were continued for a total
period of 4 days. The haemorrhagic
necrotic action was rather slower to appear
in the tumours of the heparinized animals
but the usual scabs had formed over the
tumours before the period of hepariniza-
tion was over. Some tumour regression
was observed in the heparinized mice
but the effect was greatly reduced when
compared with that seen in normal mice
(Table XI). In a similar experiment,
animals carrying FS6 fibrosarcomata were
heparinized and then treated with endo-
toxin. Tumour necrosis was reduced and
the inhibition of tumour growth was only
slight in the heparinized group (Table XI).
3. Effect of an c-adrenergic antagonist
"dibenyline "
Some of the toxic manifestations of
TABLE XI. Effect of Heparin on
Average
diameter
of ttumouir
(mm) on day
Tumour Treatment of treatment
L5178Yt Endotoxin lOlg 7-5 (7)
Heparin before 8*0 (7)
and after 10 Iug
endotoxinlH
FS6§ Endotoxin 10 yg 6-0 (10)
Heparin before 7- 0 (10)
and after 10 ,ug
endotoxinfl
* Defined in Table II.
t 2 x 106 L5178Y cells weie injected i.d.
§ 5 x 105 FS6 cells were injected i.d.
100 ,ug heparin 3 x per 24 hours. s.c.
endotoxin are attributable to the release
of catecholamines and consequent slowing
of blood flow (Levy and Blattberg, 1964).
This can be prevented by a-adrenergic
blockade and dibenyline is used clinically
to protect against the irreversible shock
syndrome of endotoxin poisoning (Levy,
North and Wells, 1954; Eckenhoff and
Cooperman, 1965). To test if the slowing
of blood flow due to the constriction of
arteriolar vessels plays a part in the anti-
tumour action of endotoxin, DBA/2 mice
bearing intradermal L5178Y lymphoma
were injected i.p. with 100 jug of dibeny-
line 2 hours before giving 10 ,ug of endo-
toxin i.p. This treatment did not reduce
the haemorrhagic necrosis following endo-
toxin but a slightly decreased antitumour
effect was recorded (Table XII). In a
further experiment where the dose of
dibenyline was increased from 100 ,tg
to 500 ,ag/mouse, the signs of haemorr-
hagic necrosis were slowerto appear in the
tumours of the dibenyline-endotoxin
group of animals, but tumour regression
still occurred.
However, dibenyline protected power-
fully against the toxic effects ofendotoxin
and made it possible to use much higher
doses of the latter. The possibility that
higher doses ofendotoxin in mice protected
by dibenyline may cause tumours to
regress which had failed to respond to
10 jtg of endotoxin was investigated with
the fibrosarcoma FS9. CBA mice carry-
9-day-old FS9fibrosarcomata wereinjected
Antitumour Action of Endotoxin
Effect on tumour growth*
,- ~~~~~~~~A
Temporary Permainent
None Slowing regression regression
0/1( 0/10 1/10 9/10
0/9 4/9 3/9 2/9
1/10
1/8
3/10
6/8
5/10
1/8
1/10
0OR
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TABLE XII.-Attempts to Block Antitumour Effects of Endotoxin with Dibenyline
Tumour Treatment
L5178Y11 Endotoxin
(10 ug)
tDibenyline
2 hours
before ug
endotoxin
Average
diameter
of tumour
(mm) on day of
treatment( )
7-5 (7)
7-5 (7)
Degree of
haemorrhagic
necrosis
Effect on tumour growth*
{ - ~~~~A_
None
0/10
Temporary
Slowing regression
0/10 1/10
+ + + + 2/10 2/10 0/10
FS91 Endotoxin 8-5 (10) +
(10 jg)
Dibenyline 7-5 (10) + +
2 hours
before
100 ug§
endotoxin
* Defined in Table II.
t 100 izg i.p. 2 hours before endotoxin also injected i.p.
§ 100,g endotoxin caused 100% mortality in CBA mice.
11 2 x 106 cells injected i.d.
105 cells injected i.d.
with 100 jug ofendotoxin 2 hours after i.p
injection of 100 ,tg of dibenyline. Table
XII shows that this tumour responded to
the higher dose of endotoxin which had
been made possible by protection with
dibenyline. We conclude that the bio-
logical effects of endotoxin, which are
protected against by dibenyline, do not
play a significant role in causing tumour
regression and that in combination with
dibenyline endotoxin can be more
effectively employed. Dibenyline, how-
ever, failed to protect against the toxic
effects ofdsRNA and did not make it poss-
ible to use a higher dose ofthis compound.
14/15 3/15 0/15 0/15
0(/5 2/5 2/5 1/5
4. Effects ofimmunosuppression
In order to investigate the involve-
ment ofimmune factors in the antitumour
effects of dsRNA and endotoxin, the
immune response of the host to its own
tumour was suppressed by either whole
body irradiation with x-rays, by corti-
costeroids or by antilymphocyte serum.
As can be seen from Table XIII whole
body irradiation totally abolished the
antitumour action against the i.d. lym-
phoma by endotoxin and by dsRNA. In
this series of experiments the dsRNA
produced no permanent regression in
the control group and there were only
TABLE XIII.-Effect of Whole Body x-irradiation on Antitumour Action of dsRNA
and Endotoxin
L5178Y lymphoma
Endotoxin dsRNA
f/ --A A_
FS6 sarcoma
endotoxin
Effect on Normal x-irradiation Normal x-irradiation Normal x-irradiation
tumour growth*
None 0/15 15/15 2/5 5/5 0/5 1/5
Slowing of 2/15 0/15 1/5 0/5 2/5 4/5
tumour growth
Temporary 0/15 0/15 2/5 0/5 2/5 0/5
regression
Permanent 13/15 0/15 0/5 0/5 1/5 0/5
regression
* Defined in Table II.
Whole body irradiation of 400 rad given 24 hours before tumour transplant. Endotoxin (10 jug) and
dsRNA (100 ,ug 2 x weekly) given i.p. Day 7 after transplant i.d. of 106 tumour cells.
Permanent
regression
9/10
6/10
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temporary regressions and a slowing of
growth. In animals that had been irradi-
ated dsRNA was totally without effect.
The influence ofwhole body irradiation on
the action of endotoxin against the flbro-
sarcoma was not so dramatic but there was
a reduction of response. This series of
experiments does not by itself prove that
an intact immutne mechanism is needed
for the antitumour action of dsRNA and
endotoxin to be manifested, since whole
body irradiation causes widespread patho-
logical changes and in particular induces
leucocytopenia. However, two other
treatments which are immunosuppressive,
namely administration of ALS and of
cortisone, botlh reduce the antitumour
action of endotoxin (Table XIV). It is
difficuilt to envisage an effect other than
immunosuppression which is shared by
whole body irradiation and treatment
with ALS or cortisone, and while the
hypothesis that an intact immune system
is needed for endotoxin and dsRNA to
cause regression of established tumours
has not been unambiguously proven by
these experiments, it is extremely likely.
It is ofinterest that haemorrhagic necrosis
still occurred in tumours of endotoxin-
treated mice that had been exposed to
whole body irradiation. Intradermal
L5178Y tumoursgrowingin micesubjected
to 400 rad 24 hours before tumour
transplant, were treated with 1 lig, 5 /,g
or 10 ,ug per mouse of endotoxin and the
degree of haemorrhagic necrosis occurring
in the tumours assessed in a " blind "
study by two individuals. It was found
that although haemorrhagic necrosis did
not occur as quickly in the irradiated
mice and did not, except in the group given
10 jug of endotoxin, reach quite the same
intensity, it did still occur whereas the
antitumour activity of endotoxin was
completely absent in the irradiated mice
(Table XIII).
DISCUSSION
With regard to all ofthe toxic manifes-
tations, including pyrexia, shock syn-
dromes, enhancement of toxicity by lead
acetate and temperature elevation, effect
on complement and blood clotting systems
and intravascular coagulation, as well as
the activation of macrophages, dsRNA
(both of viral origin and synthetic Poly I
Poly C) cannot be distinguished quali-
tatively from endotoxin and, as far as
the limited data warrant, from lipid A.
In this paper we have demonstrated that
this similarity in activities also applies to
the antitumour actions. These sub-
stances appear to have two quite distinct
effects on tumour growth (1) prophylactic
when given several days before challenge
and (2) therapeutic when given several
days after tumour implantation. With
TABLE XIV. Effect of ALS and Cortisone on Antitumour Action of Endotoxin
on Intradermal L5178Y
Treatment
None
Endot,oxint
ALS an(d
endotoxin §
Endotoxin
Cortisonie
and endotoxin
Day of
treatment
after tumour
transplant
16
16
7
7
Average
dliameter
of tuimour
on day of
treatment (mm)
12
12
6 9
7-1
Effect on tuimour growth*
Temporary Permanent
None Slowing regression regression
5/5 0/5 0/5 0/5
0/5 0/5 5/5
3/5 2/5 0/5 0/5
0/t 0/5
2/5 1/5
1/5,
1/5 1/;5
* Defined in Table II.
t 10,tg en(lotoxin injected i.p.
§ Injections of ALS given i.p. every 2 days beginning 2 days after tumour transplant.
11 I * 25 [tg prednisolone acetate injected s.c. 4 hours before endlotoxin.
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the tumours used in this study the prophy-
lactic action is only observed against an
i.p. challenge (see Table V) and not against
an s.c. challenge and, moreover, for
protection to be observed dsRNA or
endotoxin must be given several days
before challenge; they are without effect
if given one day before the tumour. The
requirements for therapy are diametrically
opposite: s.c. and i.d. respond but ascites
tumours do not. A response in s.c. and
i.d. tumours is seen only if treatment is
given several days after tumour trans-
plant.
The protective activity correlates with
the presence in the peritoneal cavity of
activated macrophages (Alexander and
Evans, 1971). Immediately after injec-
tion of dsRNA or endotoxin, macro-
phages seem to disappear from the peri-
toneal cavity and only very small numbers
can be recovered from peritoneal washings.
By the fourth day numbers increase again
and by the seventh day macrophages can
be recovered in normal yields. These,
however, are activated in that they kill
tumour cells in vitro. The hypothesis that
the protective action seen only in the
peritoneal cavity and not at subcutaneous
sites is due to activated macrophages, is
strengthened by recent studies of Hibbs,
Lambert and Remington (1971) who find
that mice chronically infected with micro-
organisms growing intracellularly are
more resistant to tumour challenge and
that their peritoneal macrophages are
"activated ".
The therapeutic effect of dsRNA and
endotoxin is more complex and the data
presented indicate that several factors
contribute. Clearly these agents do not
act directly on the tumour cells since their
growth both in vitro and in vivo is un-
affected following exposure to dsRNA
and endotoxin. Damage of blood vessels
in the tumour would appear to be impor-
tant but not by itself sufficient to cause
the regressions. The reduction of the
antitumour activity by heparin establishes
the key role of intravascular coagulation
in this process and provides an immediate
explanation why only established solid
tumours (i.e., those that have become
fullyvascularized) respond andwhy ascites
tumours are quite unaffected. On the
other hand, dsRNA and endotoxin still
induce haemorrhage in the tumours of
animals that have been exposed to 400 rad
of whole body irradiation and in tumours
of animals that have received ALS or
cortisone, yet these pre-treatments abolish
the antitumour action ofendotoxin and of
dsRNA. Also, endotoxin and dsRNA
induce haemorrhagic necrosis in some
tumours without halting their growth.
That an immune reaction of the host
directed against the tumour contributes
to the tumour regression induced by
dsRNA and endotoxin is indicated by the
fact that only strongly antigenic tumours
respond to these treatments. Moreover,
in animals that have been deliberately
immunosuppressed by ALS or whole body
irradiation, tumour regressions are not
induced. Admittedly these pre-treatments
also affect the blood clotting system, but
since haemorrhagic necrosis still occurs it
seems more likely that it is immuno-
suppression, and not some other pathology
induced by both x-rays and ALS, which
counteracts the antitumour activity of
dsRNA and endotoxin. The failure of
dibenyline to block the antitumour action
indicates that this effect is not mediated
via the action of endotoxin on the adren-
ergic nervous system.
The apparent need for both haemorr-
hagic necrosis and an active immune
response suggests that the effect ofdsRNA
and of endotoxin on tumours is due to a
breakdown of the vascular structure
which allows the various immunological
effector mechanisms of the host to gain
access to the tumour. Physical inacces-
sibility of cells in a solid tumour is one
reason for the relative immunotherapeutic
ineffectiveness of antisera and the same
may well apply to some of the cell-
mediated components of the immune
response. Vascular damage alone can
only cause a temporary slowing oftumour
growth, but when this occurs in a host
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which is reacting to an antigenic tumour,
then the combined response may result in
the regressions that are observed.
In addition to haemorrhagic necrosis
and host immunity, activation of macro-
phages may be another and parallel
mechanism in the antitumour reaction.
Evans (1972) has shown that tumours can
contain many macrophages, thus in the
FS6 sarcoma which responds to dsRNA
and endotoxin at least 40% ofthe cells are
macrophages while the FS9 a tumour
which does not usually respond-contains
only 20% macrophages.
Thus it is likely there are several factors
contributing to the tumour regression
brought about by endotoxin and dsRNA
and for the various tumour systems that
respond, these factors may contribute in
differing degrees depending on the nature
of the tumour and the route of adminis-
tration. The antitumour effects ofdsRNA
and endotoxin in L5178Y lymphoma and
fibrosarcoma FS6 differed in two respects.
Firstly, complete abolition of the dsRNA
or endotoxin-induced tumour regressions
by immunosuppression occurred only with
the lymphoma, whereas with the fibro-
sarcoma the antitumour effects were
reducedbyx-irradiationbutnotcompletely
eliminated. This latter result is more in
agreement with experiments of Fischer et
al. (1972) who utilized a fibrosarcoma and
a polyoma for their work. Secondly,
the effect of dsRNA injected directly into
the tumour was not increased in the case
of the lymphoma by repeated treatment
whereas the opposite was true of FS6
fibrosarcoma (Table VI). These differ-
ences might be explained in terms of the
varying contributions ofthe two processes
capable of causing tumour regression,
for example (1) vascular damage with the
ensuing release of immune factors and (2)
macrophage activation. The first mech-
anism would be sensitive to immuno-
suppression whereas there is evidence
that macrophage activation would not.
In vitro experiments by den Otter (unpub-
lished) show that macrophages that have
been subjected to x-irradiation can still
be activated by addition of dsRNA or
endotoxin. The low macrophage content
of intradermal L5178Y lymphomata (per-
sonal observation) compared to the 4000
present in FS6 fibrosarcomata (Evans,
1972) could be taken as further evidence
that vascular damage rather than macro-
phage activation plays a key role in the
dsRNA-endotoxin induced tumour necro-
sis of lymphoma tissue. On the other
hand, macrophage activation could be an
important component of tumour regres-
sions induced in the fibrosarcomata. The
observed increase in tumour regression
following large doses of endotoxin to mice
carrying the less antigenic fibrosarcoma
FS9 might be explained in terms ofactiva-
tion ofincreased numbers ofmacrophages.
On the basis of this hypothesis one could
predict that where macrophages form
part of the structure of the tumour and if
the drug can be supplied in sufficient
concentration locally to the tumour, then
therapy would be successful. Preliminary
results suggest that treatment of animals
carrying lung tumour (FS6 fibrosarcoma
cells injected i.v.) with large doses of
endotoxin can prolong survival times.
The available data are consistent with the
hypothesis that the contribution of macro-
phage activation to the antitumour effect
will be greatest for tumours rich in macro-
phages and when dsRNA and endotoxin
are given directly into the tumour. When
given systemically the mechanism requir-
ing vascular damage coupled with an
active immune reaction by the host may
predominate.
The finding that the polysaccharide-
free endotoxin derivative lipid A has the
structure shown in Fig. 5 (Gmeiner et al.,
1969), allows some speculation concerning
a possible molecular basis for the similarity
in action of dsRNA and endotoxin. It is
not inconceivable that both may bind to a
common receptor on cells which relies for
its specificity on a combination ofrecurring
phosphate groups, present in both macro-
molecules, and of a hydroxyl group
provided by the myristic acid in lipid A
and by ribose in dsRNA.
387388 I. PARR, E. WHEELER AND P. ALEXANDER
CH-O-®
HC-NH-
© -O-CH
hU-0
HC-0
I _________~ ~~~~~ CH
C 0HC-NH-(
(KDO)3 ---O-CH
HG-0-0
HC-
J
I H2-0- )
FIG. 5.-Structure of a lipid A unit with a
KDO oligosaccharide. FS = long chain
fatty acids. HM = fl-hydroxymyristic acid.
Published Gmeiner et al. (1969).
We wish to thank Dr R. L. Carter for
preparation and interpretation of the
histological data, Professor 0. Westphal
for supplying the endotoxin derivatives,
Dr D. A. L. Davis for the Shigella endo-
toxin and Beecham's Research Labora-
tories Ltd for the dsRNA.
This work was supported by grants
made to the Chester Beatty Research
Institute by the Medical Research Council
and the Cancer Research Campaign and
by a grant from the Napier Trust.
REFERENCES
ALEXANDER, P. & EVANS, R. (1971) Endotoxin and
Double Stranded RNA render Macrophages
cytotoxic. Nature, New Biol., 232, 76.
ANDERVONT, H. B. (1936) The Reaction of Mice and
of various Mouse Tumours to the Injection of
Bacteria] Products. Am. J. Cancer, 27, 77.
BUSCH, -. (1866) Verhandlungen arztlicher Gesell-
schaften. Klin. Wschr., 3, 245.
DR6GE, W., LEHMANN, V., LUDERITZ, 0. & WEST-
PHAL, 0. (1970) Structural Investigations on the
2-keto-3-deoxyoctonate Region of Lipopolysac-
charides. Eur. J. Biochem., 14, 175.
ECKENHOFF, J. E., COOPERMAN, L. H. (1965) The
Clinical Application of Phenoxybenzamine in
Shock and Vasoconstrictive states. Surgery,
Gynec. Obstet., 121, 483.
EVANS, R. (1972) Macrophages in Syngeneic Animal
Tumours. Transplantation, 14, 468.
FISCHER, J. C., COOPERBAND, S. R. & MANNICK,
J. A. (1972) The Effect of Polyinosinic-poly-
cytidylic acid on the Immune Response of Mice
to Antigenically Distinct Tumours. Cancer Res.,
32, 889.
GALANOS, C., RIETSCHEL, E. T., LUDERITZ, 0. &
WESTPHAL, 0. (1971) Interaction of Lipopoly.
saccharides and Lipid A with Complement. Eur.
J. Biochem., 19, 143.
GMEINER, J., LUDERITZ, 0. & WESTPHAL, 0. (1969)
Biochemical Studies on Lipopolysaccharides of
Salmonella R mutants. 6. Investigations on the
structure of the Lipid A Component. Eur. J.
Biochem., 7, 370.
GoOD, R. A. & THOMAS, L. (1953) Studies on the
Generalized Shwartzman Reaction. IV. Preven-
tion of the Local and Generalized Shwartzman
Reactions with Heparin. J. exp. Med., 97, 871.
HALPERN, B. N., Biozzi, G., STIFFEL, C. & MOULTON,
D. (1959) Correlation entre l'activite phagocytaire
du systeme reticulo-endothelial et la production
d'anticorps antibact6riens. C.r. Soc. Biol., 153,
919.
HALPERN, B. N., Biozzi, G., STIFFEL, C. & MOULTON,
D. (1966) Inhibition of Tumour Growth by Admi-
nistration of killed Corynebacterium parvum.
Nature, Lond., 212, 853.
HIBBS, J. B., JR., LAMBERT, L. H., JR. & REMING-
TON, J. S. (1971) Tumour Resistance conferred
by Intracellular Protozoa. J. clin. Inve8t., 50,
45a.
HIBBS, J. B., JR., LAMBERT, L. H., JR. & REMING-
TON, J. S. (1972) Possible Role of Macrophage
mediated Nonspecific Cytotoxicity in Tumour
Resistance. Nature, New Biol., 235, 48.
HILLEMAN, M. R. (1970) Double-stranded RNAs
(Poly I : C) in the Prevention of Viral Infections.
Arch8 intern. Med., 126, 109.
LEVY, E. Z., NORTH, W. C. & WELLS, J. A. (1954)
Modification of Traumatic Shock by Adrenergic
BlockingAgents. J.Pharmac. exp. Ther., 112.151.
LEVY, H. B., LAW, L. W. & RABSON, A. S. (1969)
Inhibition of Tumour Growth by Polyinosinic-
polycytidylic acid. Proc. natn. Acad.Sci., 62, 357.
LEVY, H. B. (1970) Interferon and Interferon
inducers in the Treatment of Malignancies.
Arch8 intern. Med., 126, 78.
LEVY, M. N. & BLAITBERG, B. (1964) In Shock.
Ed. S. G. Hershey. Boston: Little, BrownandCo.
LUDERITZ, 0. (1970) Recent Results on the Bio-
chemistry of the Cell Wall. Lipopolysaccharides
of Salmonella Bacteria. Angew. Chem., 9, 649.
MATHE, G., POUILLART, P. & LAPEYRAQUE, F. (1969)
Active Immunotherapy of L1210 Leukaemia
Applied after the Graft of Tumour Cells. Br.
J. Cancer, 23, 814.
NAUTS, H. C., FOWLER, G. A. & BOGATKO, F. H.
(1953) A Review of the Influence of Bacterial
Infection and of Bacterial Products (Coley's
Toxins) on Malignant Tumours in Man. Acta
med. 8cand., 45, Suppl. No. 276.
OLD, L. J., BENACERRAF, B., CLARKE, D. A.,
CARSWELL, E. A. & STOCKERT, E. (1961) The Role
of the Reticulo-endothelial System in the Host
Reaction to Neoplasia. Cancer Re8., 21, 1281.
PARR, I. (1972) Response of Syngeneic Murine
Lymphomata to Immunotherapy in Relation to
Antigenicity of the Tumour. Br. J. Cancer, 26,
174.
PLANTEROSE, D. N., BIRCH, P. J., PILCH, D. J. F. &
SHARPE, T. J. (1970) Antiviral Activity of dsRNA
and virus-like Particles from Penicillium Stoloni-
ferum. Nature, Lond., 227, 504.SIMILARITIES OF THE ANTI-TUMOUR ACTIONS OF ENDOTOXIN 389
PILCH. D. J. F. & PLANTEROSE, D. N. (1971) Effects
on Friend Disease of double-stranded RNA of
Fungal Origin. J. gen. Virol., 10, 155.
SHWARTZMAN, G. (1937) Phenomenon of Local Ti88ue
Reactivity and it8 Immunological, Pathological
and Clinical Significance. New York: P. B.
Hoeber Inc. p. 461.
SUTTHIWAN, P., SHORTER, R. G., HALLENBECK, G. A.
& ELVEBACK, L. R. (1969) Comparison of Rabbit
Anti-mouse thymus sera Produced after Different
Numbers ofInjections ofLymphoid Cells. Trans-
plantation, 8, 249.
WESTPHAL, 0. & LiUDERITZ, 0. (1954) Chemische
Erforschung von Lipopolysacchariden gramnega-
tiver Bakterien. Angew. Chem., 66, 407.